PANACEA BIOTEC
|
|
BOM : 531349     NSE : PANACEABIO     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward Pledged Shares : None or < 25% |
Aug 30,2024 |
Price(EOD): ₹ 224.15
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,374.04 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
PANACEA BIOTEC | -6% | 57.6% | 65.6% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 6% | 62.4% |
CIPLA | 3.9% | 7.3% | 33.9% |
DR REDDYS LABORATORIES | 1.2% | 4.2% | 20.1% |
ZYDUS LIFESCIENCES | 1.8% | -9.5% | 80.1% |
DIVIS LABORATORIES | 3.2% | 3.5% | 37.8% |
FUNDAMENTAL ANALYSIS OF PANACEA BIOTEC
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF PANACEA BIOTEC
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
-48.41
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -28.36 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 1.63
P/B Calculated based on Book Value of Rs 842.05 Cr
[Latest Year - Mar2024 - Consolidated Results ] 2.52
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 545.70 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA -31% 59% |
SHARE PRICE MOMENTUM OF PANACEA BIOTEC
PANACEA BIOTEC vs SENSEX
DEBT OF PANACEA BIOTEC
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.31 0.2 0.13 0.21 |
0.02 0.04 -3.58 -1.17 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF PANACEA BIOTEC
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF PANACEA BIOTEC
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-15.2% -131.62% -704.25% -697.99% |
-10.43% -35.69% -230.85% -244.63% |
QtrlyTrend |
-8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
PANACEA BIOTEC related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 2.5% | 7.5% | 54.8% |
S&P BSE ALLCAP | 1.2% | 1.2% | 40.7% |
S&P BSE MIDSMALLCAP | 1.1% | 1.4% | 56.7% |
S&P BSE SMALL CAP | 0.6% | 1.1% | 55% |
You may also like the below Video Courses
FAQ about PANACEA BIOTEC
Is PANACEA BIOTEC good for long term investment?
As on Aug 30,2024, the Fundamentals of PANACEA BIOTEC look Poor and hence it may not be good for long term investment ! See Financial Performance of PANACEA BIOTEC . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is PANACEA BIOTEC UnderValued or OverValued?
As on Aug 30,2024, PANACEA BIOTEC is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of PANACEA BIOTEC ?
As on Aug 30,2024, the Intrinsic Value of PANACEA BIOTEC is Rs. 233.66 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -363.92
Fair Value [Median EV / Sales Model] : Rs. 326.71
Fair Value [Median Price / Sales Model] : Rs. 140.62
Estimated Median Fair Value of PANACEA BIOTEC : Rs. 233.66
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.